A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

What is the purpose of this trial?

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors.


Participation Guidelines

Ages: 18 years and older

Gender: Both


MedImmune, Inc

Start Date: 06/13/2016

End Date: 04/01/2019

Last Updated: 02/22/2018

Study HIC#: 1505015949

Get Involved

For more information about this study, contact:
Karen Forman
+1 203-671-0783
karen.forman@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image